# 3rd CEE Meeting on Viral Hepatitis and Co-infection with HIV - Program

## WEDNESDAY 27 SEPTEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Registration and coffee</td>
</tr>
<tr>
<td>9:00</td>
<td>Opening of the meeting</td>
</tr>
</tbody>
</table>

### Session 1: Epidemiology / access to treatment

**Chairs:** Jonathan Schapiro

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10</td>
<td>Local situation in Slovenia and Balkan Countries</td>
<td>Mojca Maticic, MD, PhD</td>
<td>University of Ljubljana, Slovenia</td>
</tr>
<tr>
<td>9:20</td>
<td>Local situation in Ukraine</td>
<td>Olga Golubovska, MD</td>
<td>Bogomolets National medical University, Ukraine</td>
</tr>
<tr>
<td>9:30</td>
<td>Local situation in Russia</td>
<td>Vadim Rassokhin, MD</td>
<td>First St. Petersburg State Medical University named Acad IP Pavlov, Russia</td>
</tr>
<tr>
<td>9:40</td>
<td>Local situation in Romania</td>
<td>Oana Sandulescu, MD, PhD</td>
<td>Carol Davila University of Medicine and Pharmacy, Romania</td>
</tr>
<tr>
<td>9:50</td>
<td>Local situation in Baltic Countries</td>
<td>Saulius Caplinskas, MD, PhD</td>
<td>Lithuanian Centre for Communicable Diseases and AIDS, Lithuania</td>
</tr>
<tr>
<td>10:00</td>
<td>Local situation in Georgia</td>
<td>Akaki Abutidze, MD, MPH</td>
<td>AIDS and Clinical Immunology Research Centre, Georgia</td>
</tr>
<tr>
<td>10:10</td>
<td>Local situation in Czech and Slovak Republics</td>
<td>Viktor Aster, MD, PhD</td>
<td>Charles University, Czech Republic</td>
</tr>
<tr>
<td>10:20</td>
<td>Local situation in Turkey</td>
<td>Cihan Yurdaydin, MD, PhD</td>
<td>University of Ankara, Turkey</td>
</tr>
<tr>
<td>10:30</td>
<td>Local situation in Poland</td>
<td>Andrzej Horban, MD, PhD</td>
<td>University of Warsaw, Poland</td>
</tr>
<tr>
<td>10:40</td>
<td>Local situation in Hungary</td>
<td>Béla Hunyady, MD, PhD</td>
<td>Somogy County Kaposi Mór Teaching Hospital, Hungary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:15</td>
<td>Hep-CORE study: management of HBV and HCV infections throughout Europe</td>
</tr>
</tbody>
</table>
11:40  **New testing strategies for HCV: how can we achieve the WHO targets?**  
Mario Poljak, MD, PhD  
University of Ljubljana, Slovenia

12:05  **Round table discussion: access to HepC treatment**

**Introduction to Access to HepC treatment in EECA**  
Liudmyla Maistat  
Medicines Patent Pool, Switzerland

**Key barriers to HepC treatment for PWIDs**  
Eberhard Schatz  
Corellation Network, the Netherlands

**Direct price negotiations**  
Natalia Kravchenko  
Alliance for Public Health, Ukraine

**Compulsory licensing and patent opposition**  
Sergei Golovin  
Treatment Preparedness Coalition, Russia

**Medicine Patent Pool’s progress in voluntary licensing**  
Liudmyla Maistat  
Medicines Patent Pool, Switzerland

13:00  Group picture

13:15  Lunch break

14:00  Industry-sponsored symposium (p. 30, 32)

### Session 2  Challenges in the management of HCV infected patients  
Chairs: Jürgen Rockstroh and Milosz Parczewski

15:00  **Management of HCC in HCV-infected patients**  
Markus Peck-Radosavljevic, MD  
Klinikum Klagenfurt am Wörthersee, Austria

15:30  **Clinical case: re-treatment of HCV DAA failure with 3-class resistance**  
Pavel Khaykin, MD  
MainFachArzt, Germany

15:50  Discussion

16:00  Coffee break

### Session 3  Epidemiology, clinical presentation and management of hepatitis E virus

16.30  **Management of hepatitis E virus**  
Heiner Wedemeyer, MD  
Medical School Hannover, Germany
THURSDAY 28 SEPTEMBER

8:30 Industry-sponsored symposium (p. 33)

Session 4 Treatment challenges in HIV & HCV – special populations

9:30 Special challenges in curbing the HIV epidemic in Central/Eastern Europe
Mitosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland

Abstract - driven presentations:

10:00 Results of Hepatitis C virus (hcv) treatment program among people with HIV/HCV co-infection who inject drugs (PWID)
Mr. Sergii Filipovich, Ukraine

10:10 HIV infection outbreak among IDUs in Minsk
Prof. Vladimir Eremin, Belarus

10:20 Discussion

10:30 Coffee break

Session 5 Abstract - driven presentations

11:00 Real-world effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program
Prof. Tengiz Tsertsvadze, Georgia

11:10 Clinical characteristics of patients seeking care for chronic HCV infection – results from the large observational study in Central and Eastern European region and Kazakhstan (MOSAIC Study)
Dr. Béla Hunyady, Hungary
11:20 Changes in demographic, epidemiological and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010
Dr. Nina Kmet Lunarcek, Slovenia

11:30 Prognostic factors for liver fibrosis regression following sustained virologic response in patients with hepatitis C treated with direct acting antivirals
Dr. Oana Sandulescu, Romania

11:40 Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia
Prof. Ligita Jancoriene, Lithuania

11:50 Discussion

Special session: Future directions of ARVs

12:00 Virologist perspective
Charles Boucher, MD, PhD
Erasmus University, the Netherlands

12:15 Clinician perspective
Jonathan Schapiro, MD
Sheba Medical Centre, Israel

12:30 Pharmacologist perspective
Saye Khoo, MD, PhD
University of Liverpool, United Kingdom

12:45 Discussion

13:00 Lunch break

Session 6 Future in diagnostic & therapeutic approaches

13:45 Innovative diagnostics for HIV, HBV and HCV
Dan Otelea, MD, PhD
Nat. Institute for Inf. Diseases “Prof. Dr. Matei Bals”, Romania

14:15 The challenges in hepatitis B vaccination
Pierre Van Damme, MD, PhD
University of Antwerp, Belgium

14:45 Discussion

15:00 Closing remarks